ES2090714T3 - Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico. - Google Patents

Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.

Info

Publication number
ES2090714T3
ES2090714T3 ES92925051T ES92925051T ES2090714T3 ES 2090714 T3 ES2090714 T3 ES 2090714T3 ES 92925051 T ES92925051 T ES 92925051T ES 92925051 T ES92925051 T ES 92925051T ES 2090714 T3 ES2090714 T3 ES 2090714T3
Authority
ES
Spain
Prior art keywords
matrix
therapeutic agent
glass matrix
biologically
prolonged release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925051T
Other languages
English (en)
Inventor
Siva N Raman
John P Cunningham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Veterinary Inc
Original Assignee
Mallinckrodt Veterinary Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25184119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2090714(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mallinckrodt Veterinary Inc filed Critical Mallinckrodt Veterinary Inc
Application granted granted Critical
Publication of ES2090714T3 publication Critical patent/ES2090714T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UNA COMPOSICION PARA LA LIBERACION ININTERRUMPIDA DE UN AGENTE TERAPEUTICO ACTIVO BIOLOGICAMENTE EN DONDE LA MATRIZ DE LA COMPOSICION DE LIBERACION ININTERRUMPIDA SE COMPONE DE UNA MATRIZ DE VIDRIO DE CARBOHIDRATO AMORFO QUE CONSTA DE UN CARBOHIDRATO ADECUADO Y UN AGENTE QUE RETARDA LA RECRISTALIZACION DEL CARBOHIDRATO Y UN AGENTE TERAPEUTICO ACTIVO BIOLOGICAMENTE Y UNA CERA INSOLUBLE EN AGUA DISPERSADA A TRAVES DE LA MATRIZ. AGENTES TERAPEUTICOS ACTIVOS BIOLOGICAMENTE QUE PUEDEN SER INCORPORADOS DENTRO DE LA MATRIZ DE VIDRIO DE CARBOHIDRATO INCLUYEN PROLACTIN, HORMONAS DE CRECIMIENTO, ALBUMINAS SERUM, FACTORES DE CRECIMIENTO Y FRAGMENTOS ACTIVOS BIOLOGICAMENTE O FORMA RECOMBINANTE DEL MISMO.
ES92925051T 1991-12-05 1992-11-02 Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico. Expired - Lifetime ES2090714T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80258191A 1991-12-05 1991-12-05

Publications (1)

Publication Number Publication Date
ES2090714T3 true ES2090714T3 (es) 1996-10-16

Family

ID=25184119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925051T Expired - Lifetime ES2090714T3 (es) 1991-12-05 1992-11-02 Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.

Country Status (11)

Country Link
US (1) US5356635A (es)
EP (1) EP0615438B1 (es)
CN (1) CN1065439C (es)
AT (1) ATE140620T1 (es)
AU (1) AU3125193A (es)
CA (1) CA2125148C (es)
DE (1) DE69212497T2 (es)
DK (1) DK0615438T3 (es)
ES (1) ES2090714T3 (es)
TW (1) TW337488B (es)
WO (1) WO1993010758A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
EP0748213B1 (en) 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US5817327A (en) * 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
SK283026B6 (sk) * 1994-08-04 2003-02-04 Quadrant Holdings Cambridge Limited Tuhý časticový prostriedok na terapeutické použitie a spôsob jeho prípravy
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JPH10508744A (ja) 1994-09-22 1998-09-02 クオドラント ホールディングス ケンブリッジ リミテッド 運動競技の間の水分補給および栄養摂取の用途のための組成物ならびにその製造法
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
ATE239451T1 (de) * 1995-06-07 2003-05-15 Elan Drug Delivery Ltd Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
EP2272536B1 (en) 1996-06-26 2016-05-04 Board of Regents, The University of Texas System Hot-melt extrudable Pharmaceutical formulation
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6149939A (en) * 1997-05-09 2000-11-21 Strumor; Mathew A. Healthful dissolvable oral tablets, and mini-bars
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
WO1999038495A2 (en) * 1998-01-30 1999-08-05 Scios Inc. Controlled release delivery of peptide or protein
KR19990071255A (ko) * 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6207193B1 (en) * 1999-12-27 2001-03-27 Stephen E. Feldman Transdermal drug delivery system
AU2001238540A1 (en) 2000-02-24 2001-09-03 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
KR20030023878A (ko) 2000-06-26 2003-03-20 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 계면활성제 함유비수성 제제들
US6664234B1 (en) * 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
EP1313425B1 (en) * 2000-07-14 2007-03-07 Novo Nordisk A/S Method of moulding a pharmaceutical composition in a packaging material
RU2259817C2 (ru) * 2000-10-13 2005-09-10 Кембридж Байостэбилити Лтд. Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1781264B1 (en) 2004-08-04 2013-07-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
EP3103477A1 (en) 2004-09-17 2016-12-14 Durect Corporation Sustained local anesthetic composition containing saib
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
BRPI0613731A2 (pt) * 2005-07-12 2011-02-01 Renovo Ltd composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
EP3326621A1 (en) 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
WO2009111649A2 (en) * 2008-03-05 2009-09-11 Regenerative Research Foundation Methods and compositions for delivery of exogenous factors to nervous system sites
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US8481308B2 (en) 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CN107249570B (zh) * 2014-11-21 2022-08-09 丹麦技术大学 用于局部药物释放的凝胶制剂
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10758567B2 (en) * 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
BR112018073493A2 (pt) * 2016-05-20 2019-03-26 Technical University Of Denmark composição de marcador palpável, método e kit de partes para identificar e/ou localizar um tumor não palpável, um tumor palpável com maior precisão e/ou um tecido alvo, e, uso de uma composição de marcador palpável
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
EP3630201A1 (en) * 2017-05-24 2020-04-08 Technical University of Denmark Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation DELAYED-RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED PROCEDURES
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2413419A (en) * 1943-02-27 1946-12-31 Searle & Co Pellet for administering gonadotropic pituitary hormones
US2918411A (en) * 1957-11-01 1959-12-22 Olin Mathieson Pharmaceutical preparations
FR2383659A1 (fr) * 1977-03-16 1978-10-13 Berri Balzac Procede de preparation de comprimes contenant des substances labiles en microdispersion
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4857506A (en) * 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
WO1989004689A1 (en) * 1987-11-16 1989-06-01 Baxter International Inc. Glassy matrix for administration of beneficial agent
EP0345628B1 (en) * 1988-06-07 1993-05-12 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins

Also Published As

Publication number Publication date
TW337488B (en) 1998-08-01
DK0615438T3 (da) 1996-11-11
CA2125148A1 (en) 1993-06-10
CN1072861A (zh) 1993-06-09
EP0615438A1 (en) 1994-09-21
ATE140620T1 (de) 1996-08-15
DE69212497D1 (de) 1996-08-29
EP0615438B1 (en) 1996-07-24
CN1065439C (zh) 2001-05-09
CA2125148C (en) 1999-05-11
WO1993010758A1 (en) 1993-06-10
AU3125193A (en) 1993-06-28
DE69212497T2 (de) 1996-12-12
US5356635A (en) 1994-10-18

Similar Documents

Publication Publication Date Title
ES2090714T3 (es) Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
DK0695172T3 (da) Fast præparat med hurtig frigørelse, dets fremstilling og dets anvendelse
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
ES2045470T3 (es) Formulaciones medicinales en aerosol.
AR036972A1 (es) Tableta bioadhesiva de hidratacion progresiva y liberacion sostenida y su uso en la fabricacion de un agente farmaceutico
ES2157944T3 (es) Nucleos de pastillas de liberacion inmediata de medicamentos insolubles que poseen un recubrimiento de liberacion sostenida.
MY101593A (en) Sustained release preparation.
DK372786D0 (da) Farmaceutiske praeparater af phenindamin
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
ES2167453T3 (es) Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.
ATE79549T1 (de) Nicht-sedative antihistaminica enthaltende husten-/schnupfenmittel.
AR006484A1 (es) Composición farmacéutica con efecto anestésico, uso de esta composición para la fabricación de medicamentos, y proceso para la fabricación de esta composición .
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
ES2151968T3 (es) Composiciones hemorroidales y metodo de utilizacion.
ES2111547T3 (es) Comprimido de liberacion prolongada.
ES2145557T3 (es) Composiciones de ablandamiento del agua y composiciones detergentes.
UY25544A1 (es) Forma de dosificación de nefazodona
ES2051733T3 (es) Procedimiento de obtencion de un medicamento a base de tamoxifen para uso local.
GR3025362T3 (en) Sol-controlled gelatine-based thermocolloidal matrix for peroral prolonged action administration forms.
DE60002719D1 (de) Ophthalmische zusammensetzungen in form wässriger gele
ATE254851T1 (de) Iod-herstellungszusammensetzung
ES2036670T3 (es) Composicion para prevenir una alergia de contacto por administracion simultanea de un corticoesteroide con un farmaco sensibilizante.
ES2133152T3 (es) Composicion de tiotepa liofilizada estable.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 615438

Country of ref document: ES

FG2A Definitive protection

Ref document number: 615438

Country of ref document: ES